Evidence map›Paper›PMID 27733575›Full record

ArticleJournal of leukocyte biology2017

Frontline Science: D1 dopaminergic receptor signaling activates the AMPK-bioenergetic pathway in macrophages and alveolar epithelial cells and reduces endotoxin-induced ALI.

Nathaniel B Bone, Zhongyu Liu, Jean-Francois Pittet, Jaroslaw W Zmijewski

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Anti-Inflammatory Effects of Peripheral Dopamine.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Review
  6. Association of COVID-19 with Comorbidities: An Update.ACS pharmacology & translational science · 2023
    Review
  7. Dopamine, Immunity, and Disease.Pharmacological reviews · 2023
    Review
  8. Citicoline and COVID-19: vis-à-vis conjectured.Naunyn-Schmiedeberg's archives of pharmacology · 2022
    Review
  9. Article
  10. Treatment paradigms in Parkinson's Disease and Covid-19.International review of neurobiology · 2022
    Article
  11. COVID-19: The cynosure of rise of Parkinson's disease.International review of neurobiology · 2022
    Article
  12. ZKSCAN3 in severe bacterial lung infection and sepsis-induced immunosuppression.Laboratory investigation; a journal of technical methods and pathology · 2021
    Article
  13. Article
  14. Article
  15. Parkinson's Disease and the COVID-19 Pandemic.Journal of Parkinson's disease · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nathaniel B BoneDepartment of Medicine, University of Alabama, Birmingham, Alabama, USA; and.
Zhongyu LiuDepartment of Medicine, University of Alabama, Birmingham, Alabama, USA; and.
Jean-Francois PittetDepartment of Anesthesiology, University of Alabama, Birmingham, Alabama, USA.
Jaroslaw W ZmijewskiDepartment of Medicine, University of Alabama, Birmingham, Alabama, USA; and zmijewsk@uab.edu.
University of Alabama at Birmingham · US

Funding

AMPK activation and acute lung injuryR01HL107585 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZMIJEWSKI, JAROSLAW WALDEMAR · 2012 to 2015
$1.4M
NHLBI NIH HHS R01 HL107585
6 · The paper itself

Abstract

Catecholamines, including β-adrenergic and dopaminergic neurotransmitters, have an essential role in regulating the "fight or flight" reflex and also affects immune cell proinflammatory action. However, little is known about whether catecholamines prevent dysfunction of metabolic pathways associated with inflammatory organ injury, including development of acute lung injury (ALI). We hypothesize that selected catecholamines may reduce metabolic alterations in LPS-stimulated macrophages and in the lungs of mice subjected to endotoxin-induced ALI, a situation characterized by diminished activity of AMP-activated protein kinase (AMPK). We found that activation of the dopamine 1 receptor (D1R) with fenoldopam, but not stimulation of adrenergic receptors with norepinephrine, resulted in a robust activation of AMPK in peritoneal macrophages, human monocytes, or alveolar epithelial cells (AECs). Such AMPK activation was mediated by a phospholipase C (PLC)-dependent mechanism. Unlike norepinephrine, D1R activation also prevented Thr172-AMPK dephosphorylation and kinase inactivation in LPS-treated macrophages. Furthermore, we show that a culture of AECs with either fenoldopam or the AMPK activator metformin effectively diminished IL-1β-induced release of adverse paracrine signaling, which promotes the macrophage proinflammatory response. In vivo, fenoldopam reduced the severity of LPS-induced ALI, including development of pulmonary edema, lung permeability, and production of inflammatory cytokines TNF-α, MIP-2, or KC and HMGB1. Fenoldopam also prevented AMPK dephosphorylation in the lungs of LPS-treated mice and prevented loss of mitochondrial complexes NDUFB8 (complex I) and ATP synthase (complex V). Collectively, these results suggest that dopamine is coupled to AMPK activation, which provides a substantial anti-inflammatory and bioenergetic advantage and reduces the severity of endotoxin-induced ALI.

Indexed as

Energy MetabolismSignal TransductionAcute Lung InjuryAlveolar Epithelial CellsAMP-Activated Protein KinasesAnimalsCytokinesElectron TransportEndotoxinsEnzyme ActivationFenoldopamHumansInflammationLipopolysaccharidesLungMacrophagesAMP-Activated Protein KinasesCytokinesEndotoxinsFenoldopamLipopolysaccharidesReceptors, AdrenergicReceptors, Dopamine D1Type C PhospholipasesARDScatecholaminesdopamineimmune homeostasisLPSpulmonary

Identifiers

PMID27733575
PMCPMC5235905
OpenAlexW2530291491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.